Use of catalyst pharmacophore models for screening of large combinatorial libraries

Journal of Chemical Information and Computer Sciences

Volumn 42, Issue 5, 2002, Pages 1204-1211

  Hecker, Evan A ^a   Duraiswami, Chaya ^a   Andrea, Tariq A ^a   Diller, David J ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYST PHARMACOPHORE MODELS;

COMPUTER SIMULATION; DATABASE SYSTEMS; MOLECULAR STRUCTURE; PHARMACODYNAMICS;

ENZYMES;

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; ENZYME INHIBITOR; PROTEIN SERINE THREONINE KINASE;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; GENETICS; IN VITRO STUDY; MOLECULAR GENETICS; STATISTICS;

AMINO ACID SEQUENCE; BINDING SITES; CDC2-CDC28 KINASES; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN-SERINE-THREONINE KINASES;

EID: 0036708534     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci020368a     Document Type: Article

References (31)

1. Catalyst v4.5. Molecular Simulations, I; San Diego, CA.
2. Ghose, A.K.; Wendoloski, J.J. Pharmacophore Modelling: Methods, Experimental Verification and Application. Perspect. Drug Discovery Des. 1998, 253-271.
3. Charifson, P.S. Practical Application of Computer-Aided Drug Design; Marcel Dekker: New York, 1997.
4. Traxler, P.; Green, J.; Mett, H.; Sequin, U.; Furet, P. Use of a Pharmacophore Model for the Design of EGFR Tyrosine Kinase Inhibitor: Isoflavones and 3-Phenyl-4(1H)-quinolones. J. Med. Chem. 1999, 42, 1018-1026.
5. Ward, J.S.; Merritt, L.; Calligaro, D.O.; Bymaster, F.P.; Shannon, H.E.; Mitch, C.H.; Whitesitt, C.; Brunsting, D.; Sheardown, M.J.; Olesen, P.H.; Swedberg, M.D.B.; Jeppesen, L.; Sauerberg, P. 1,2,5-Thiadiazole Analogues of Aceclidine as Potent m1 Muscarinic Agonists. J. Med. Chem. 1998; 41, 379-392.
6. Grigorov, M.; Weber, J.; Tronchet, J.M.J.; Jefford, C.W.; Milhous, W.K.; Maric, D.A QSAR Study of the Antimalarial Activity of Some Synthetic 1,2,4-Trioxanes. J. Chem. Inf. Comput. Sci. 1997, 37, 124-130.
7. Keller, P.A.; Bowman, M.; Dang, K.H.; Garner, J.; Leach, S.P.; Smith, R.; McCluskey, A. Pharmacophore Development for Corticotropin-Releasing Hormone: New Insights into Inhibitor Activity. J. Med. Chem. 1999, 42, 2351-2357.
8. Kaminski, J.J.; Rane, D.F.; Snow, M.E.; Weber, L.; Rothofsky, M.L.; Anderson, S.D.; Lin, S.L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112.
9. Sprague, P.W. Automated Chemical Hypothesis Generation and Database Searching with Catalyst. Perspect. Drug Discovery Des. 1995, 3, 1-20.
10. Nicklaus, M.C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G.W.A.; Pommier, Y. HIV-1 Integrase Pharmocophore: Discovery of Inhibitors through Three-Dimensional Database Searching. J. Med. Chem. 1997, 40, 920-929.
11. McGregor, M.J.; Muskal, S.M. Pharmacophore Fingerprinting. 1. Application to QSAR and Focused Library Design. J. Chem. Inf. Comput. Sci. 1999, 39, 569-574.
12. McGregor, M.J.; Muskal, S.M. Pharmacophore Fingerprinting. 2. Application to Primary Library Design. J. Chem. Inf. Comput. Sci. 2000, 40, 117-125.
13. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of Common Functional Configurations Among Molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 563-571.
14. Guuer, O.F. Pharmacophore Perception, Development, and Use in Drug Design; IUL: La Jolla, CA, 2000.
15. Smellie, A.; Kahn, S.D.; Teig, S.L. Analysis of Conformational Coverage. 2. Applications of Conformational Models. J. Chem. Inf. Comput. Sci. 1995, 35, 295-304.
16. Smellie, A.; Kahn, S.D.; Teig, S.L. Analysis of Conformational Coverage. 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-294.
17. Smellie, A.; Teig, S.L.; Towbin, P. Poling: promoting conformational variation. J. Comput. Chem. 1995, 16, 171-187.
18. Sielecki, T.M.; Boylan, J.F.; Benfield, P.A.; Trainor, G.L. Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation. J. Med. Chem. 2000, 43, 1-18.
19. DeBondt, H.L.; Rosenblatt, J.; Jancarik, J.; Jones, H.D.; Morgan, D.O.; Kim, S.-H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
20. Jeffrey, P.D.; Russo, A.A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376, 313-320.
21. Schow, S.R.; Mackman, R.L.; Blum, C.L.; Brooks, E.; Horsma, A.G.; Joly, A.; Kerwar, S.S.; Lee, G.; Shiffman, D.; Nelson, M.G.; Wang, X.; Wick, M.M.; Zhang, X.; Lum, R.T. Synthesis and Activity of 2,6,9-Trisubstituted Purines. Bioorg. Med. Chem. Lett. 1997, 7, 2697-2702.
22. Furet, P.; Zimmerman, J.; Capraro, H.-G.; Meyer, T.; Imbach, P. Structure based design of potent CDK1 inhibitors derived from olomoucine. J. Comput.-Aided Mol. Design 2000, 14, 403-409.
23. Gray, N.S.; Wodicka, L.; Thunniessen, A.-M.W.H.; Norman, T.C.; Kwon, S.; Espinoza, H.; Morgan, D.O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D.J.; Schultz, P.G. Exploiting Chemical Libraries, Structure, and Geuomics in the Search for Kinase Inbibitors. Science 1998, 281, 533-538.
24. Carlson, B.A.; Dubay, M.M.; Sausville, E.A.; Brizuela, L.; Worland, P.J. Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-Dependent Kinase CDK2 and CDK4 in Human Breast Carcinoma Cells. Cancer Res. 1996, 56, 2973-2978.
25. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J.J.; Donella-Deana, A.; Pinna, L.; Letham, D.S.; Kato, J.Y.; Detivand, L.; Leclerc, S.; Meijer, L. Inhibition of Cyclin-Dependent Kinases by Purine Analogues. Eur. J. Biochem. 1994, 224, 771-786.
26. Barvian, M.; Boschelli, D.H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
27. Imbach, P.; Capraro, H.G.; Furet, P.; Mett, H.; Meyer, T.; Zimmermann, J. 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 91-96.
28. Kim, K.S.; Sack, J.S.; Tokarski, J.S.; Qian, L.; Chat, S.T.; Leith, L.; Kelly, Y.F.; Misra, R.N.; Hunt, J.T.; Kimball, S.D.; Humphreys, W.G.; Wautlet, B.S.; Mulherou, J.G.; Webster, K.R. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem. 2000, 43, 4126-4134.
29. Murthi, K.K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M.D.; Worland, P.J.; Mansuri, M.M.; Pal, K. Structure-activity relationship studies of flavopiridol analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037-1041.
30. Ohlmeyer, M.H.J.; Swanson, R.N.; Dillard, L.; Reader, J.C.; Asouline, G.; Kobayashi, R.; Wigler, M.; Still, W.C. Complex synthetic chemical libraries indexed with molecular tags. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10922-10926.
31. De Azevedo, W.F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S.H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.